| Literature DB >> 26893941 |
Sung Il Choi1, Soon Kil Kim1, Sungha Park2, Ju Han Kim3, Sang Hyun Ihm4, Gwang-Il Kim5, Woo Shik Kim6, Wook Bum Pyun7, Yu-Mi Kim8, Jinho Shin1.
Abstract
BACKGROUND: Resistant hypertension (RH) may be one of the cause of the plateau in improving the control rate in hypertension (HT) management. The misdiagnosis of RH by clinic blood pressure (BP) is important clinical problem. Aim of the study were to investigate the prevalence of RH by ambulatory blood pressure monitoring (ABPM) and the factor associated with control status of ambulatory BPs.Entities:
Keywords: Ambulatory blood pressure monitoring; Hypertension; Hypertension Resistant to Conventional Therapy; Masked hypertension; White-coat hypertension
Year: 2016 PMID: 26893941 PMCID: PMC4750808 DOI: 10.1186/s40885-016-0045-x
Source DB: PubMed Journal: Clin Hypertens ISSN: 2056-5909
The uses of antihypertensive medications in 1230 study subjects according to the optimal disage criteria
| Count by any dosage | Count by 50 % or more of recommended dose |
| |
|---|---|---|---|
| Angiotensin receptor blocker | 714 (57.9 %) | 705 (57.2 %) | 0 |
| ACE inhibitor | 166 (13.5 %) | 157 (12.7 %) | 0 |
| Beta blocker | 530 (43.0 %) | 456 (37.0 %) | < 0.0001 |
| Calcium antagonist | 732 (59.4 %) | 727 (59.0 %) | 0.03 |
| Dihydrochlorthiazide | 259 (21.0 %) | 235 (19.1 %) | <0.0001 |
| Indapamide | 19 (1.5 %) | 19 (1.5 %) | 0 |
| Loop diuretics | 49 (4.0 %) | 47 (3.8 %) | 0.16 |
| Spironolactone | 20 (1.6 %) | 20 (1.6 %) | 0 |
| Categories of antihypertensive drug regimen | |||
| 3 drugs including diuretics | 72 (5.9 %) | 83 (6.7 %) | <0.0001 |
| 4 drugs | 105 (8.5%) | 83 (6.7 %) | |
| other 1 or more drugs | 1053(85.6 %) | 1064(86.5 %) |
ACE angiotensin converting enzyme, * p value for McNemar chi square test
Agreement between clinic blood pressure and ambulatory blood pressure to classify resistant hypertension
| Clinic BP |
| Kappa | |||
|---|---|---|---|---|---|
| Non-RH | RH | (95% confidence interval) | |||
| Daytime BP | Non-RH | 19 (10.7 %) | 12 (6.8 %) | 0.53 | |
| RH | 12 (6.8 %) | 134 (75.7 %) | 1 | (0.3658 ~ 0.6956) | |
| Nighttime BP | Non-RH | 11 (6.2 %) | 7 (4.0 %) | 0.37 | |
| RH | 20 (11.3 %) | 139 (78.5 %) | 0.01 | (0.1813 ~ 0.5539) | |
| 24 h BP | Non-RH | 17 (9.6 %) | 8 (10.2 %) | 0.53 | |
| RH | 14 (7.9%) | 138 (78.0%) | 0.2 | (0.3638 ~ 0.7049) | |
BP blood pressure, RH resistant hypertension defined by uncontrolled BP by each criteron or BP control needing four or more antihypertensive medications. *,p for McNemar test
Agreement between clinic blood pressure and ambulatory blood pressure in the control status in the subject taking three or more drugs
| Clinic BP (mmHg) | p* | Kappa | |||
|---|---|---|---|---|---|
| <140/90 | > = 140/90 | (95 % confidence interval) | |||
| Daytime BP (mmHg) | <135/85 | 30 (16.9 %) | 25 (14.1 %) | 0.29 | |
| > = 135/85 | 30 (16.9 %) | 92 (52.1 %) | 0.5 | (0.1443 ~ 0.4402) | |
| Nighttime BP (mmHg) | <120/70 | 19 (10.7 %) | 18 (10.2 %) | 0.18 | |
| > = 120/70 | 41 (23.2) | 99 (55.9 %) | 0 | (0.0328 ~ 0.3264) | |
| 24 h BP (mmHg) | <130/80 | 27 (15.3 %) | 18 (10.2 %) | 0.32 | |
| > = 130/80 | 33 (18.6 %) | 99 (55.9 %) | 0.04 | (0.1680 ~ 0.4627) | |
BP blood pressure, *, p for McNemar test
The comparison according to control status by daytime blood pressure of 135/85 mmHg or greater in response to three or more antihypertensive medications including diuretics
| Controlled BP group | Uncontrolled BP group |
| |
|---|---|---|---|
| ( | ( | ||
| Age (yr) | 61.6 ± 11.2 | 61.2 ± 10.4 | 0.84 |
| Body mass index (Kg/m2) | 25.7 ± 4.1 | 25.6 ± 3.3 | 0.83 |
| Abdominal circumference (cm) | 93.8 ± 10.9 | 91.9 ± 9.3 | 0.28 |
| Clinic systolic BP (mmHg) | 135.1 ± 18.2 | 153.8 ± 24.1 | <0.0001 |
| Clinic diastolic BP (mmHg) | 80.2 ± 12.3 | 91.5 ± 16.1 | <0.0001 |
| Heart rate (beats per minute) | 73.7 ± 14.4 | 75.2 ± 14.8 | 0.58 |
| Potassium (mEq/L) | 4 ± 0.4 | 4.1 ± 0.5 | 0.37 |
| Creatinine (mg/dL) | 1 ± 0.3 | 0.9 ± 0.2 | 0.14 |
| Cholesterol (mg/dL) | 171.4 ± 40.7 | 182.9 ± 44.9 | 0.17 |
| Fasting blood glucose (mg/dL) | 114.2 ± 34 | 109.6 ± 34.6 | 0.53 |
| Hemoglobin A1C (%) | 6.6 ± 1.9 | 6.3 ± 1.1 | 0.37 |
| Triglyceride (mg/dL) | 128.3 ± 54.2 | 148.4 ± 81 | 0.19 |
| High density lipoprotein (mg/dL) | 46.7 ± 13.1 | 45.8 ± 10 | 0.67 |
| Daytime systolic BP (mmHg) | 121.8 ± 7.9 | 149.6 ± 15.2 | <0.0001 |
| Daytime diastolic BP (mmHg) | 74.8 ± 5.3 | 90.9 ± 11.7 | <0.0001 |
| Daytime heart rate (bpm) | 71.4 ± 9.6 | 73.9 ± 10.2 | 0.14 |
| Nighttime systolic BP (mmHg) | 115.5 ± 14 | 138.5 ± 20.5 | <0.0001 |
| Nighttime diastolic BP (mmHg) | 71 ± 9.7 | 83.6 ± 15.4 | <0.0001 |
| Nighttime heat rate (bpm) | 61.8 ± 10.3 | 64.8 ± 11.3 | 0.11 |
| 24 h systolic BP (mmHg) | 121 ± 8.9 | 146.9 ± 15.3 | <0.0001 |
| 24 h diastolic BP (mmHg) | 73.9 ± 5.8 | 89.5 ± 12.7 | <0.0001 |
| 24 h heart rate (bpm) | 68.6 ± 9.3 | 71.3 ± 10 | 0.11 |
| Smoking | 14.6 % | 11.5 % | 0.57 |
| Drinking | 29.1 % | 32.8 % | 0.62 |
| Regular physical activity | 43.6 % | 36.9 % | 0.39 |
| Family history of SCD | 3.6 % | 6.6 % | 0.35 |
| Family history of hypertension | 36.4 % | 46.7 % | 0.2 |
| Metabolic syndrome | 47.3 % | 44.3 % | 0.71 |
| High global CV risk | 89.1 % | 84.3 % | 0.4 |
| Cardiovascular disease history | 60.0 % | 45.1 % | 0.07 |
| Coronary artery disease | 36.4 % | 26.5 % | 0.18 |
| Stroke | 14.8 % | 9.0 % | 0.25 |
| Heart failure | 18.5 % | 5.8 % | 0.01 |
| Antihypertensive medication | |||
| ACE inhibitor | 14.5 % | 22.1 % | 0.24 |
| Angiotensin receptor blocker | 69.1 % | 78.7 % | 0.17 |
| Beta blocker | 56.4 % | 74.6 % | 0.02 |
| Calcium antagonist | 50.9 % | 69.7 % | 0.02 |
| Diuretics | 100.0 % | 99.2 % | 0.5 |
| Thiazide | 70.9 % | 78.5 % | 0.27 |
| Indapamide | 7.3 % | 5.8 % | 0.71 |
| Spironolactone | 5.5 % | 6.6 % | 0.77 |
| Loop diuretics | 21.8 % | 10.7 % | 0.05 |
| Alpha blocker | 1.8 % | 2.5 % | 0.41 |
| Vasodilator | 0.0 % | 2.5 % | 0.55 |
| Aspirin | 50.1 % | 54.1 % | 0.76 |
| Statin | 40.0 % | 40.9 % | 0.9 |
ACE angitensin converting enzyme, BP blood pressure, CV cardiovascular, SCD sudden cardiac death
Multiple logistic regression analysis and odds ratios for the factors associated with the resistant group to antihypertensive theraphy using 3 or more antihypertensive medications including diuretics
| Clinic BP | Daytime BP | Nighttime BP | 24 h BP | |
|---|---|---|---|---|
| 3 140/90 mmHg | 3 135/85 mmHg | 3 120/70 mmHg | 3 130/80 mmHg | |
| Age | 0.989[0.978 ~ 1.001] | 0.992[0.98 ~ 1.004] | 0.996[0.983 ~ 1.009] | 0.992[0.98 ~ 1.005] |
| Male sex | 0.956[0.71 ~ 1.288] | 1.221[0.901 ~ 1.655] | 1.171[0.836 ~ 1.639] | 1.157[0.84 ~ 1.594] |
| Metabolic syndrome | 0.965[0.743 ~ 1.253] | 1.037[0.793 ~ 1.357] | 0.963[0.717 ~ 1.294] | 1.043[0.786 ~ 1.385] |
| Smoking | 1.202[0.791 ~ 1.827] | 1.161[0.75 ~ 1.797] | 0.624[0.399 ~ 0.976] | 1.008[0.639 ~ 1.59] |
| Drinking | 1.135[0.843 ~ 1.528] | 1.242[0.913 ~ 1.688] | 1.512[1.072 ~ 2.133] | 1.4[1.01 ~ 1.942] |
| Regular physical exercise | 0.826[0.636 ~ 1.073] | 0.855[0.654 ~ 1.119] | 0.99[0.735 ~ 1.335] | 0.869[0.654 ~ 1.153] |
| Family history of hypertension | 1.231[0.947 ~ 1.6] | 1.131[0.865 ~ 1.48] | 1.121[0.834 ~ 1.507] | 1.169[0.88 ~ 1.552] |
| Diabetes mellitus | 0.917[0.685 ~ 1.226] | 0.791[0.589 ~ 1.062] | 1.172[0.837 ~ 1.64] | 0.919[0.673 ~ 1.256] |
| History of stroke | 1.166[0.786 ~ 1.73] | 1.042[0.701 ~ 1.549] | 1.391[0.874 ~ 2.214] | 1.063[0.699 ~ 1.617] |
| History of coronary artery disease | 0.619[0.458 ~ 0.835] | 0.632[0.465 ~ 0.859] | 0.604[0.431 ~ 0.846] | 0.605[0.44 ~ 0.832] |
| History of heart failure | 0.896[0.495 ~ 1.623] | 0.559[0.309 ~ 1.009] | 0.638[0.345 ~ 1.179] | 0.646[0.354 ~ 1.178] |
| CKD | 1.08[0.709 ~ 1.646] | 1.025[0.67 ~ 1.569] | 1.298[0.79 ~ 2.133] | 1.293[0.815 ~ 2.051] |
| Beta blocker | 0.962[0.731 ~ 1.265] | 0.838[0.634 ~ 1.107] | 1.017[0.746 ~ 1.385] | 0.742[0.554 ~ 0.994] |
| Calcium antagonist | 1.527[1.176 ~ 1.982] | 1.589[1.218 ~ 2.074] | 1.705[1.271 ~ 2.288] | 1.411[1.066 ~ 1.868] |
| ACE inhibitor or ARB | 1.42[1.083 ~ 1.863] | 1.479[1.122 ~ 1.95] | 1.273[0.938 ~ 1.728] | 1.376[1.03 ~ 1.837] |
| Loop diuretics | 0.755[0.405 ~ 1.408] | 0.54[0.289 ~ 1.011] | 0.454[0.24 ~ 0.861] | 0.541[0.288 ~ 1.014] |
| Optimal dosage use | 1.283[0.838 ~ 1.965] | 1.285[0.836 ~ 1.976] | 1.15[0.72 ~ 1.838] | 1.086[0.696 ~ 1.696] |
ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, BP blood pressure, CKD chronic kidney disease with eGFR between 30 and 60 ml/min/1.73m2
Fig. 1Demographic and clinical factors related to uncontrolled BP group when treated with three or more antihypertensive medications including diuretics. In the upper panel, CAD history, the use of calcium channel blocker or the use of ACEI/ARB were significant factor for uncontrolled BP group. In the lower left panel, additionally smoking, drinking, and loop diuretics were significantly related factor for uncontrolled BP group defined by nighttime BP ≥ 120/70 mmHg. In the lower right panel, CAD history, the use of calcium channel blocker or the use of ACEI/ARB were associated with uncontrolled BP group defined by 24 h BP ≥ 130/80 mmHg. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure ; CAD, coronary artery disease; CKD, chronic kidney disease; DM, diabetes mellitus; HT, hypertension